Skip to main content
CALC
NASDAQ Life Sciences

Co-Founders & Directors Invest $300K in Recent Private Placement

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$0.992
Mkt Cap
$16.272M
52W Low
$0.461
52W High
$7.2
52W Position info
115% above low
Off High info
86% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

CALC has more than doubled off its 52-week low of $0.461.

Summary

CalciMedica's co-founders and directors, Eric Roberts and Rachel Leheny, invested a combined $300,000 in the company's recent private placement, signaling strong insider confidence.


Key Events · Ownership and Investor Activity · CALC

  • Significant Insider Investment

    Co-founders and directors Eric Roberts and Rachel Leheny collectively purchased 373,458 units in the recent private placement for approximately $300,000.

  • Participation in Recent Financing

    This investment was part of the private placement announced on June 24, 2026, which secured up to $49 million for the company.

  • Increased Beneficial Ownership

    Eric Roberts now beneficially owns 6.4% of the company, and Rachel Leheny owns 6.3%, reflecting their continued significant stake.


Analysis · CALC · Life Sciences

This Schedule 13D/A reveals that co-founders and managing directors Eric Roberts and Rachel Leheny collectively invested approximately $300,000 in CalciMedica's recent private placement. This significant insider participation, representing nearly 2% of the company's market capitalization, demonstrates strong conviction from key leadership following the company's recent financing and clinical trial updates. It provides more complete detail than the previously reported Form 4.

How filings like this one have moved

In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CALC was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.3M. The 52-week trading range was $0.46 to $7.20. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CALC - Latest Insights

CALC
Sep 02, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.20
Real-time Price: $1.90 info
Change: -$0.300 (-14%) info
Market Cap: $12.974M info
CALC
Aug 27, 2026, 9:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.540
Real-time Price: $1.90 info
Change: Reverse Stock Split info
Market Cap: $12.974M info
CALC
Aug 27, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.5479
Real-time Price: $1.90 info
Change: Reverse Stock Split info
Market Cap: $12.974M info
CALC
Aug 21, 2026, 5:00 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.5699
Real-time Price: $1.90 info
Change: Reverse Stock Split info
Market Cap: $12.974M info
CALC
Aug 19, 2026, 6:36 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.646
Real-time Price: $1.90 info
Change: Reverse Stock Split info
Market Cap: $12.974M info